Intech Investment Management LLC cut its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 31.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 110,838 shares of the biopharmaceutical company’s stock after selling 51,454 shares during the quarter. Intech Investment Management LLC’s holdings in Halozyme Therapeutics were worth $12,237,000 at the end of the most recent reporting period.
A number of other hedge funds have also modified their holdings of HALO. Hilton Head Capital Partners LLC acquired a new stake in shares of Halozyme Therapeutics during the third quarter worth $33,000. CoreCap Advisors LLC lifted its holdings in shares of Halozyme Therapeutics by 98.0% during the third quarter. CoreCap Advisors LLC now owns 303 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 150 shares during the last quarter. MidFirst Bank purchased a new stake in shares of Halozyme Therapeutics during the second quarter valued at $27,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in shares of Halozyme Therapeutics in the 2nd quarter valued at $28,000. Finally, Quantbot Technologies LP acquired a new position in shares of Halozyme Therapeutics in the 2nd quarter valued at $30,000. 97.79% of the stock is currently owned by institutional investors and hedge funds.
Halozyme Therapeutics Price Performance
Shares of NASDAQ:HALO opened at $96.50 on Tuesday. The company’s fifty day moving average is $114.29 and its two-hundred day moving average is $85.63. The company has a quick ratio of 3.60, a current ratio of 3.88 and a debt-to-equity ratio of 13.50. Halozyme Therapeutics, Inc. has a 12-month low of $61.22 and a 12-month high of $134.00. The company has a market cap of $11.00 billion, a P/E ratio of 18.07, a price-to-earnings-growth ratio of 0.38 and a beta of 0.92.
Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) last released its earnings results on Thursday, November 5th. The biopharmaceutical company reported $2.39 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.30 by $0.09. The company had revenue of $492.97 million during the quarter, compared to analyst estimates of $491.63 million. Halozyme Therapeutics had a return on equity of 751.81% and a net margin of 26.93%. The company’s revenue for the quarter was up 39.1% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.72 earnings per share. Equities analysts expect that Halozyme Therapeutics, Inc. will post 8.34 earnings per share for the current fiscal year.
Insiders Place Their Bets
In related news, Director Matthew L. Posard sold 18,996 shares of the stock in a transaction dated Wednesday, September 16th. The stock was sold at an average price of $107.74, for a total value of $2,046,629.04. Following the completion of the sale, the director directly owned 58,839 shares of the company’s stock, valued at approximately $6,339,313.86. This represents a 24.41% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 20,000 shares of the stock in a transaction dated Monday, November 16th. The stock was sold at an average price of $98.38, for a total value of $1,967,600.00. Following the completion of the sale, the chief executive officer directly owned 767,780 shares of the company’s stock, valued at approximately $75,534,196.40. This represents a 2.54% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 144,226 shares of company stock worth $15,262,493 in the last quarter. 2.50% of the stock is currently owned by corporate insiders.
Analyst Upgrades and Downgrades
A number of equities analysts recently weighed in on the company. Zacks Research cut Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, November 11th. Citigroup reaffirmed a “market outperform” rating on shares of Halozyme Therapeutics in a research note on Friday, August 7th. TD Cowen reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a research note on Monday. Leerink Partners cut shares of Halozyme Therapeutics from an “outperform” rating to a “hold” rating and raised their target price for the stock from $110.00 to $117.00 in a report on Friday, November 6th. Finally, JPMorgan Chase & Co. lifted their target price on shares of Halozyme Therapeutics from $78.00 to $79.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 3rd. Seven equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $108.18.
Read Our Latest Analysis on Halozyme Therapeutics
About Halozyme Therapeutics
Halozyme Therapeutics, Inc. is a biotechnology company focused on developing drug-delivery technologies and medicines. Its ENHANZE platform uses a recombinant human hyaluronidase enzyme, rHuPH20, to temporarily modify tissue under the skin and help enable the subcutaneous administration of certain biologic medicines that might otherwise require intravenous infusion. Halozyme licenses ENHANZE to pharmaceutical and biotechnology partners, which use the technology in their own products. The company also markets Hylenex recombinant, a hyaluronidase product used to facilitate the dispersion and absorption of other injected medicines and fluids.
Read More
- Five stocks we like better than Halozyme Therapeutics
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report).
Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
